We engineer the microbiome with unprecedented precision to prevent, treat or cure microbiome-associated diseases. Join us!
Location: France, Ile-de-France, Paris
Total raised: $35M
Investors 2
| Date | Name | Website |
| - | Agoranov | agoranov.c... |
| - | CARB-X | carb-x.org |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.05.2025 | Grant | $5M | - |
| 05.12.2023 | Series B | $30M | - |
Mentions in press and media 8
| Date | Title | Description |
| 14.05.2025 | The Rise of Biotech: A New Era of Innovation and Investment | In the world of biotechnology, the stakes are high and the rewards can be life-changing. Recent funding rounds reveal a landscape ripe with potential. Companies like Azafaros and Eligo Bioscience are leading the charge, armed with innovativ... |
| 13.05.2025 | Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology | Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance PARIS, May... |
| 13.05.2025 | Eligo Bioscience Secures $5M Grant | Eligo Bioscience, a Paris, France-based biotechnology company pioneering the development of novel genetic medicines, received a $5M grant from the French government. The funding is part of the call for proposals “Innovations in Biotherapies... |
| 10.07.2024 | Eligo Publishes in Nature a Landmark Study That Unlocks Genome Editing of Bacteria in the Gut | PARIS, July 10, 2024 /PRNewswire/ -- For the first time, a team of scientists at Eligo has demonstrated it was possible to genetically modify bacteria with nearly 100% efficiency directly in the gut of animals. This work provides scientists... |
| 05.12.2023 | Eligo Bioscience Raises $30M in Series B Funding | Eligo Bioscience, a Paris, France-based gene-editing company, raised $30M in Series B funding. The round was led by Sanofi Ventures with participation from new investor Bpifrance (through its InnoBio 2 fund), and existing investors Khosla V... |
| 15.06.2022 | After 3 years away, BIO marked by first-time handshakes and a drive to survive a bear market’s claws | Six days after the World Health Organization officially declared COVID-19 a global pandemic on March 11, 2020, Shafique Virani, M.D., landed a brand new job. Following a two-year stint leading a couple of subsidiaries of BridgeBio, the Roch... |
| 11.01.2021 | Could Crispr Eradicate Acne? | Eligo Bioscience's management team from left: CEO Xavier Duportet, PhD, Chief Business Officer, ... [+] Aurélie Grienenberger, PhD, and CSO David Bikard, PhDEligo Bioscience |
| - | Eligo Bioscience | “Eligo Bioscience is deploying in vivo gene editing technologies against microbiome targets to address diseases with high unmet needs.” |